– 13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and…
– 03 December 2024
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
– 18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
– 15 November 2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with…
– 23 October 2024
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its…
– 23 September 2024
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare…
– 20 September 2024
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary…
– 10 June 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary…
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 209 Press Releases
–
12 March 2025
12 March 2025
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
PARIS, FRANCE, March 12th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today the appointment of Olivia Brown as, EVP, Global Head of Neurotoxins, effective April 1st, 2025. She will serve on Ipsen’s Executive Leadership…
–
13 February 2025
13 February 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
–
03 December 2024
03 December 2024
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
PARIS, FRANCE; 03 December 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Biomunex Pharmaceuticals today announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of cytotoxic T cells called Mucosal-Associated…
–
18 November 2024
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
PARIS, FRANCE, 18 November, 2024 Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay® from two Phase III open-label…
–
15 November 2024
15 November 2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE® study at the American Association for…
Your dedicated contacts
-
Media Relations
-
Stay updated